Wed, Nov 26, 2014, 8:21 AM EST - U.S. Markets open in 1 hr 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • richrd_cc richrd_cc Sep 29, 2013 9:28 PM Flag

    Bottom Line - Results lo date look excellent

    Ganetespib is showing some excellent results when combined with docetaxel in the majority of patients in the study thus far. Final results should confirm the results to date before the end of the year. One major point that came out of the presentation was that the addition of ganetespib to docetaxel delayed the time for secondary lesions to occur by two-fold. This is highly indicative of longer survival which is being seen in over 70% of the patients.

    The safety profile of ganetespib warrants the use of the drug in, (at the very least), chemosensitive patients. My guess is that oncologists would rather start patients out on the dual treatment instead of waiting for bronchoscopy and lab results to determine the likelihood of PFS/OS improvement. The fact that ganetespib appears to also work in improving results in breast cancer may result in the drug being tested and ultimately used in many different cancers in the future.

    This drug may not be a first line treatment but it seems that the drug will be useful in many different cancer treatment modalities in the future.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNTA
3.10-0.03(-0.96%)Nov 25 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Deere & Company
NYSETue, Nov 25, 2014 4:04 PM EST
Jarden Corp.
NYSETue, Nov 25, 2014 4:00 PM EST
Infoblox Inc.
NYSETue, Nov 25, 2014 4:01 PM EST